Prestige Consumer Healthcare Inc
NYSE:PBH
Intrinsic Value
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. [ Read More ]
The intrinsic value of one
PBH
stock under the Base Case scenario is
73.3
USD.
Compared to the current market price of 70.47 USD,
Prestige Consumer Healthcare Inc
is
Undervalued by 4%.
Prestige Consumer Healthcare Inc's market capitalization is 3.5B USD.
PBH stock price is 70.47 USD.
PBH stock price (70.47 USD) is 4% less than its Intrinsic Value (73.3 USD).
PBH stock price (70.47 USD) is 13% less than its Relative Value (81.18 USD). Open Relative Valuation
PBH has negative Net Income for the last twelve months.
PBH's Revenue has grown by 2% over the past 12 months.
PBH's Revenue is forecast to grow at a rate of 2% per year over the next 3 years.
PBH has positive three-year average ROE (Return on Equity): 8%. The company is efficient at transforming stockholders' equity into net income.
PBH's Revenue has been growing by 6% per year for the last 3 years.
PBH's ROIC (Return on Invested Capital) has decreased in the last 3 years from 7% to -1%.
PBH has positive three-year average ROIC (Return on Invested Capital): 6%. The company is efficient at using invested capital to generate operating income.
PBH's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1%.
PBH has negative Operating Income for the last twelve months.
PBH's ROE (Return on Equity) for the past 12 months is negative and is equal to -5%.
PBH's D/E (Debt to Equity) is very low and is equal to 0.75.
PBH's ROE (Return on Equity) has significantly decreased in the last 3 years from 13% to -5%.
PBH's Altman Z-Score is equal to 1.98.
PBH's long-term assets (3B USD) exceed its long-term liabilties (2B USD).
PBH has positive Free Cash Flow for the last twelve months.
PBH has positive Gross Profit for the last twelve months.
PBH's short-term assets (394m USD) exceed its short-term liabilties (127m USD).
PBH has positive Net Debt. This means that the company has more debt (1B USD) than cash and short-term investments (64m USD).
PBH doesn't generate enough operating income (-21m USD) to safely cover interest payments on its debt (67m USD).
Valuation Backtest
Prestige Consumer Healthcare Inc
Run backtest to discover the historical profit from buying and selling
PBH
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Prestige Consumer Healthcare Inc
Balance Sheet Decomposition
Prestige Consumer Healthcare Inc
| Current Assets | 393.8m |
| Cash & Short-Term Investments | 63.6m |
| Receivables | 174.3m |
| Other Current Assets | 155.9m |
| Non-Current Assets | 2.9B |
| PP&E | 83.3m |
| Intangibles | 2.9B |
| Other Non-Current Assets | 6.3m |
| Current Liabilities | 127.4m |
| Accounts Payable | 39.3m |
| Accrued Liabilities | 80m |
| Other Current Liabilities | 8.1m |
| Non-Current Liabilities | 1.6B |
| Long-Term Debt | 1.2B |
| Other Non-Current Liabilities | 412.2m |
Earnings Waterfall
Prestige Consumer Healthcare Inc
|
Revenue
|
1.1B
USD
|
|
Cost of Revenue
|
-507.8m
USD
|
|
Gross Profit
|
626.4m
USD
|
|
Operating Expenses
|
-647.1m
USD
|
|
Operating Income
|
-20.7m
USD
|
|
Other Expenses
|
-60m
USD
|
|
Net Income
|
-80.7m
USD
|
Free Cash Flow Analysis
Prestige Consumer Healthcare Inc
PBH Profitability Score
Profitability Due Diligence
Prestige Consumer Healthcare Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Prestige Consumer Healthcare Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
PBH Solvency Score
Solvency Due Diligence
Prestige Consumer Healthcare Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Prestige Consumer Healthcare Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PBH Price Targets Summary
Prestige Consumer Healthcare Inc
According to Wall Street analysts, the average 1-year price target for
PBH
is 77.11 USD
with a low forecast of 65.65 USD and a high forecast of 88.2 USD.
Ownership
PBH Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PBH Price
Prestige Consumer Healthcare Inc
| Average Annual Return | 24.95% |
| Standard Deviation of Annual Returns | 35.01% |
| Max Drawdown | -9% |
| Market Capitalization | 3.5B USD |
| Shares Outstanding | 49 649 300 |
| Percentage of Shares Shorted | 4.88% |
Company Profile
Prestige Consumer Healthcare Inc
Country
Industry
Market Cap
Dividend Yield
Description
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 505 full-time employees. The company went IPO on 2005-02-10. The firm operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its brands include BC/Goody's, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Fleet, Gaviscon, Luden's, Monistat, Nix, Summer's Eve, Fess and Hydralyte. Its subsidiaries include Blacksmith Brands, Inc., C.B. Fleet TopCo, LLC, C.B. Fleet HoldCo, LLC, C.B. Fleet, LLC, C.B. Fleet Company, Incorporated and C.B. Fleet Investment Corporation.
Contact
IPO
Employees
Officers
The intrinsic value of one
PBH
stock under the Base Case scenario is
73.3
USD.
Compared to the current market price of 70.47 USD,
Prestige Consumer Healthcare Inc
is
Undervalued by 4%.
You don't have any saved screeners yet
